No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: Final long-term report of a prospective randomized trial

Journal of Clinical Oncology

Volumn 34, Issue 22, 2016, Pages 2568-2574

  Demeestere, Isabelle ^a,j   Brice, Pauline ^f   Peccatori, Fedro A ⁱ   Kentos, Alain ^b   Dupuis, Jehan ^g   Zachee, Pierre ^e   Casasnovas, Olivier ^h   Van Den Neste, Eric ^c   Dechene, Julie ^a   De Maertelaer, Viviane ^a   Bron, Dominique ^d   Englert, Yvon ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e Stuivenberg General Hospital   (Belgium)

^f St Louis Hospital   (Belgium)

^g HENRI MONDOR HOSPITAL   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^j Campus Erasme (Bat GE)   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLLITROPIN; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MUELLERIAN INHIBITING FACTOR; NORETHISTERONE ACETATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TRIPTORELIN; VINBLASTINE; VINCRISTINE; GONADORELIN; NORETHISTERONE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FERTILITY PRESERVATION; FOLLOW UP; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; OVARIAN PRESERVATION; OVARIAN RESERVE; OVERALL SURVIVAL; PREGNANCY OUTCOME; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSPLANTATION CONDITIONING; AGONISTS; DRUG EFFECTS; FERTILITY; LYMPHOMA; MIDDLE AGED; OVARY; PHYSIOLOGY; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES;

ADULT; FEMALE; FERTILITY; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHOMA; MIDDLE AGED; NORETHINDRONE; OVARY; PRIMARY OVARIAN INSUFFICIENCY; PROSPECTIVE STUDIES; TRIPTORELIN PAMOATE;

EID: 84979265954     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.8864     Document Type: Article

References (23)

1. Cancer Research UK: http://www.cancer researchuk.org
2. Turner NH, Partridge A, Sanna G, et al: Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: The benefit remains uncertain. Ann Oncol 24: 2224-2235, 2013
3. Oktay K, Turan V: Failure of ovarian suppression with gonadotropin-releasing hormone analogs to preserve fertility: An assessment based on the quality of evidence. JAMA Oncol 2:74-75, 2016
4. Del Mastro L, Lambertini M: Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy for fertility preservation: Toward the end of the debate? Oncologist 20: 1233-1235, 2015
5. Peccatori F, Demeestere I: GnRH analogue for chemotherapy-induced ovarian damage: Too early to say? Fertil Steril 92:e33; author reply e34, 2009
6. Moore HC, Unger JM, Phillips KA, et al: Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-932, 2015
7. Del Mastro L, Boni L, Michelotti A, et al: Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA 306:269-276, 2011
8. Lambertini M, Boni L, Michelotti A, et al: Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: A randomized clinical trial. JAMA 314:2632-2640, 2015
9. Elgindy E, Sibai H, Abdelghani A, et al: Protecting ovaries during chemotherapy through gonad suppression: A systematic review and meta-analysis. Obstet Gynecol 126:187-195, 2015
10. Gerber B, Ortmann O: Prevention of Early Menopause Study (POEMS): Is it possible to preserve ovarian function by gonadotropin releasing hormone analogs (GnRHa)? Arch Gynecol Obstet 290:1051-1053, 2014
11. Demeestere I, Brice P, Peccatori FA, et al: Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 31:903-909, 2013
12. Knauff EA, Eijkemans MJ, Lambalk CB, et al: Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 94:786-792, 2009
13. Meirow D: Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 169: 123-131, 2000
14. Levine JM, Kelvin JF, Quinn GP, et al: Infertility in reproductive-age female cancer survivors. Cancer 121:1532-1539, 2015
15. Lambertini M, Ceppi M, Poggio F, et al: Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A metaanalysis of randomized studies. Ann Oncol 26:2408-2419, 2015
16. Kalantaridou SN, Nelson LM: Premature ovarian failure is not premature menopause. Ann N Y Acad Sci 900:393-402, 2000
17. Waxman JH, Ahmed R, Smith D, et al: Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 19:159-162, 1987
18. Behringer K, Wildt L, Mueller H, et al: No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advancedstage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 21: 2052-2060, 2010
19. Behringer K, Mueller H, Goergen H, et al: Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 31: 231-239, 2013
20. Behringer K, Thielen I, Mueller H, et al: Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 23:1818-1825, 2012
21. Oktay K, Sönmezer M: Gonadotropin-releasing hormone analogs in fertility preservation-lack of biological basis? Nat Clin Pract Endocrinol Metab 4: 488-489, 2008
22. Horicks F, Van Den Steen G, Houben S, et al: Folliculogenesis is not fully inhibited during GnRH analogues treatment in mice challenging their efficiency to preserve the ovarian reserve during chemotherapy in this model. PLoS One 10:e0137164, 2015
23. Bildik G, Akin N, Senbabaoglu F, et al: GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. Hum Reprod 30: 2912-2925, 2015